scholarly journals NADPH Oxidase p22phox C242T Polymorphism and Ischemic Cerebrovascular Disease: An Updated Meta-Analysis

2015 ◽  
Vol 21 ◽  
pp. 231-238 ◽  
Author(s):  
Chao Qin
Keyword(s):  
Nadph Oxidase ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Ischemic Cerebrovascular Disease ◽  
C242t Polymorphism

scholarly journals Association between NADPH Oxidase p22phox C242T Polymorphism and Ischemic Cerebrovascular Disease: A Meta-Analysis

PLoS ONE ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. e56478 ◽  
Author(s):  
Bing-Hu Li ◽  
Li-Li Zhang ◽  
Bei-Bei Zhang ◽  
Yan-Wei Yin ◽  
Li-Meng Dai ◽  
...  
Keyword(s):  
Nadph Oxidase ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Ischemic Cerebrovascular Disease ◽  
C242t Polymorphism

scholarly journals C242T Polymorphism of NADPH Oxidase p22PHOXGene and Ischemic Cerebrovascular Disease in the Japanese Population

Stroke ◽  
2000 ◽  
Vol 31 (4) ◽  
pp. 936-939 ◽  
Author(s):  
Daisuke Ito ◽  
Mitsuru Murata ◽  
Kiyoaki Watanabe ◽  
Tadashi Yoshida ◽  
Ikuo Saito ◽  
...  
Keyword(s):  
Nadph Oxidase ◽  
Cerebrovascular Disease ◽  
Japanese Population ◽  
Ischemic Cerebrovascular Disease ◽  
C242t Polymorphism

Toll-like receptor 4 gene Asp299Gly polymorphism in ischemic cerebrovascular disease: a meta-analysis

2013 ◽  
Vol 124 (4) ◽  
pp. 252-260 ◽  
Author(s):  
Yan-Wei Yin ◽  
Jing-Cheng Li ◽  
Bing-Hu Li ◽  
Jing-Zhou Wang ◽  
Yun Liu ◽  
...  
Keyword(s):  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Toll Like Receptor ◽  
Toll Like Receptor 4 ◽  
Ischemic Cerebrovascular Disease

APOE genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis

Neurology ◽  
1999 ◽  
Vol 53 (6) ◽  
pp. 1308-1308 ◽  
Author(s):  
M. O. McCarron ◽  
D. Delong ◽  
M. J. Alberts
Keyword(s):  
Risk Factor ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Apoe Genotype ◽  
Ischemic Cerebrovascular Disease

scholarly journals Lumbrokinase Reduced the Fibrinogen Concentration in Ischemic Cerebrovascular Disease Patients: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 9 (1) ◽  
pp. 43
Author(s):  
Yedy P. Sukmawan
Keyword(s):  
Systematic Review ◽  
Confidence Interval ◽  
Cerebrovascular Disease ◽  
Meta Analysis ◽  
Control Group ◽  
Fibrinogen Concentration ◽  
Ischemic Cerebrovascular Disease ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Google Search

Lumbrokinase has been used to treat stroke and cardiovascular disease. Fibrinogen elevation is a known risk factor and a powerful predictor of ischemic cerebrovascular disease. The objective of this study was to conduct a systematic review and meta-analysis of the effects of lumbrokinase treatment on fibrinogen concentration and blood and plasma viscosities. The search strategy included articles indexed by PubMed and other resources (Google Search), using medical subject headings (MeSH) and text words. A total of 185 articles were identified; however, only two articles were included in the final analysis, including 727 patients. The results demonstrated a significant reduction in the fibrinogen concentration (–0.67, 95% confidence interval [95% CI] [–1.22, –0.12]; p=0.02) and a significant reduction in plasma viscosity (–0.77, 95% CI [–1.06, –0.48]; p=0.00001) for the lumbrokinase-treatment group compared with the control group. However, no significant difference in blood viscosity was observed between the two groups (–0.61, 95% CI [–1.33, 0.11]; p=0.10). Lumbrokinase may be effective as an adjuvant drug alongside the standard treatment for ischemic cerebrovascular disease. However, these results should be interpreted with caution due to high heterogeneity, and further randomized controlled trials are necessary.Keywords: Fibrinogen, ischemic cerebrovascular disease, lumbrokinase Lumbrokinase Menurunkan Konsentrasi Fibrinogen pada Pasien Penyakit Iskemik Serebrovaskular: Kajian Sistematik dan Meta-AnalisisAbstrakLumbrokinase telah digunakan untuk penatalaksanaan strok dan penyakit kardiovaskular. Peningkatan konsentrasi fibrinogen telah diketahui sebagai faktor risiko dan prediktor yang sangat kuat untuk penyakit iskemik serebrovaskular. Tujuan review sistematik dan meta-analisis ini adalah untuk menganalisis efek lumbrokinase terhadap konsentrasi fibrinogen, viskositas darah dan viskositas plasma. Strategi pencarian artikel meliputi pencarian artikel pada database PubMed dan sumber lainnya (Worldwide Website/Google Search) dengan menggunakan medical subject heading (MeSH) dan textword. Sebanyak 185 artikel teridentifikasi, tetapi hanya 2 artikel (melibatkan 727 pasien) yang memenuhi kriteria inklusi. Hasil analisis menunjukkan bahwa lumbrokinase dapat menurunkan konsentrasi fibrinogen dibandingkan terhadap kelompok kontrol (–0,67, 95% CI [–1,22, –0,12] ; p=0,02). Selain itu, lumbrokinase juga dapat menurunkan viskositas plasma secara signifikan bila dibandingkan dengan kelompok kontrol (–0,77, 95% confidence interval [95% CI] [–1,06, –0,48]; p=0,00001). Efek lumbrokinase terhadap viskositas darah, meskipun terjadi penurunan terhadap viskositas darah, tidak menunjukkan signifikansi bila dibandingkan kelompok kontrol (–0,61, 95% CI [–1,33, 0,11]; p=0,10). Lumbrokinase mungkin efektif untuk penyakit iskemik serebrovaskular, namun hasil ini harus diinterpretasikan dengan hati-hati disebabkan heterogenitas yang tinggi, selain itu diperlukan lebih banyak penelitian dengan desain randomized controlled trial.Kata kunci: Fibrinogen, lumbrokinase, penyakit iskemik serebrovaskular

Platelet Hyperaggregability in Ischemic Cerebrovascular Disease and Effects of Aspirin

1982 ◽  
Vol 48 (02) ◽  
pp. 117-119 ◽  
Author(s):  
M Kusunoki ◽  
K Kimura ◽  
K Nagatsuka ◽  
Y Isaka ◽  
O Uyama ◽  
...  
Keyword(s):  
Cerebrovascular Disease ◽  
Venous Blood ◽  
Second Phase ◽  
Cerebral Angiogram ◽  
Peripheral Venous Blood ◽  
Chronic Stage ◽  
Ischemic Cerebrovascular Disease ◽  
Carotid Arterial ◽  
Platelet Hyperaggregability ◽  
The Brain

SummaryPlatelet aggregation was studied in 24 patients in the chronic stage of ischemic cerebrovascular disease (CVD), with cerebral affluent and effluent blood, i.e., carotid arterial and internal jugular venous blood, and also with peripheral venous blood. Aggregation tests were performed at various final concentrations of sodium arachidonate (A.A.) and ADP. In 17 patients, not taking aspirin, platelet aggregability in jugular venous blood was significantly accentuated compared with that in arterial and peripheral venous blood. This tendency was more marked in the patients with cerebral artery stenosis and/or occlusion than in those with normal cerebral angiogram. In 7 patients taking 500 mg or more oral aspirin, aggregation differences across the brain were not observed and A.A. aggregation and the second phase of ADP aggregation were completely suppressed. These results suggest that a prophylactic administration of aspirin may be beneficial for patients in chronic stage of CVD.

Sign in / Sign up

Export Citation Format

Share Document